shutterstock_1512490073
shutterstock_1542909788

ENGINEERED SKIN SUBSTITUTE (ESS) - Autologous, full-thickness skin grafts for pediatric severe burns and other dermatological conditions.

Engineered Skin Substitute (ESS) is a full thickness skin replacement product prepared from autologous (patient’s own) tissue-engineered skin cells in development for the treatment of severe burns. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a functional skin barrier. Most importantly, self-to-self skin grafts for autologous skin tissue are less likely to be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which immune system rejection is a possibility. ESS has been used in an investigator initiated clinical setting in over 130 human subjects, primarily pediatric patients, for the treatment of severe burns up to 95% total body surface area. ESS received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.

Amarantus recently completed the acquisition of Cutanogen Corporation (Cutanogen) from Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute.

Amarantus expects to commence a Phase 2 study of ESS in the U.S. in the second quarter of 2016.

CUT DIRECT HOSPITAL COSTS BY 50%+

• Significantly reduced length of Stay in ICU/Hospital
• Significantly improved rehabilitation: physical (significantly less with ESS), mental and emotional
• Significantly reduced revision surgeries: mandatory in pediatric patients (substantially less with ESS)

ESS IS READY FOR PHASE III CLINICAL TRIALS